Where Will Recursion Pharmaceuticals Be in 5 Years?
Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at all) as it does now on Wall Street. Although things have changed on that front, Recursion has not benefited from the skyrocketing interest in AI companies. Its stock has plunged over the past four years and is currently not far from its 52-week low of $3.79.
If it can bounce back and generate solid returns in the next five years, now is about as good a time as any to invest in the company. But how likely is that? Let's find out how things might evolve for Recursion Pharmaceuticals through the end of the decade.
Image source: Getty Images.
Source Fool.com
